Tazobactam (sodium salt)

A β-lactamase inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
50mg

￥550.00

440.00

- +
100mg

￥762.00

610.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Tazobactam is a β-lactamase inhibitor [1]. Tazobactam shows intrinsic activity against Acinetobacter strains.

The β-Lactamases are responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome β-lactamase-mediated resistance, β-lactamase inhibitors have been introduced into clinical practice [2].

Tazobactam alone showed an MIC of ≤ 8 mg/liter (range 2 to 32 mg/liter) against 29 of the 38 strains [1]. Tazobactam in combination with the ureidopenicillin, piperacillin successfully restored the activity of piperacillin against β-lactamase-producing bacteria [3]. Tazobactam exhibited inhibitory activity and protected piperacillin against Richmond and Sykes types II, III, IV and V β-lactamases, staphylococcal penicillinase and extended-spectrum β-lactamases [3]. Tazobactam showed species-specific activity against class I chromosomally-mediated enzymes [3].

Preliminary clinical data indicated that the fixed combination of piperacillin /tazobactam was effective in the treatment of moderate to severe polymicrobial infections, including skin, intra-abdominal and soft-tissue and lower respiratory tract infections [3]. Piperacillin/tazobactam in combination with an aminoglycoside was effective in the empirical treatment of fever in patients with neutropenia. In phase III trials, piperacillin/tazobactam showed a tolerability profile typical of a penicillin agent [3].

参考文献:
[1] Higgins P G, Wisplinghoff H, Stefanik D, et al.? In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains[J]. Antimicrobial agents and chemotherapy, 2004, 48(5): 1586-1592.
[2] Drawz S M, Bonomo R A.? Three decades of β-lactamase inhibitors[J]. Clinical microbiology reviews, 2010, 23(1): 160-201.
[3] Perry C M, Markham A.? Piperacillin/tazobactam[J]. Drugs, 1999, 57(5): 805-843.